PHIN-214 by PharmaIN for Portal Hypertension: Likelihood of Approval
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension. According to GlobalData, Phase I drugs for Portal Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PHIN-214 LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.PHIN-214 overviewPHIN-214 is under development for the treatment of portal hypertension in compensated cirrhosis. It is a terlipressin derivative administered subcutaneously and acts by targeting vasopressin V1A (V1a) receptor.PharmaIN overviewPharmaIN is a product development biopharma company that offers drug-delivery technologies. It discovers and develops PHIN-1138 used for treatment of heart failure. Its pipeline products comprise PHIN-438, PHIN-1722, and PHIN-103 therapies for the treatment of metabolic, ascites and hepato-renal syndromes, and auto-immune syndromes, among others. PharmaIN also develops and licenses drug delivery technologies. The company offers protected graft copolymer a drug carrier technology that maximizes therapeutic potential of a drug. It operates in partnerships with other drug developers to improve and enable therapeutic molecules. PharmaIN is headquartered in Bothell, Washington, the US. For a complete picture of PHIN-214's drug-specific PTSR and LoA scores, buy the report here.
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
What's Your Reaction?
